Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Search
Fighting against rabies through vaccination and education
Dr. Silvina Muñiz is sharing her insights about rabies prevention and explains why education is essential.
Mareks Disease Poultry Chicken
Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Generalized pustular psoriasis at EADV
Dr. Emmanuelle Clerisme-Beaty reflects on the latest developments for generalized pustular psoriasis at this year’s virtual EADV congress
Equiphoria helping stroke patients hippotherapy
To further research, we're partnering with Equiphoria, a French therapy center for hippotherapy.
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Empowering all employees
Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession
Bringing Precision to Psychiatry
Dr. Hugh Marston and Dr. Vikas Mohan Sharma discuss how precision psychiatry can enable people living with mental health conditions to thrive.
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Our Curiosity Never Stops
Dr. Cornelia Dorner-Ciossek shares her thoughts on the future of brain disease research.
Is artificial intelligence the future of farming?
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.